Anti-CLL1 antibody and use thereof
US12358990B2 · kind B2 · utility
0Cited by
1References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 22, 2020 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | Feb 7, 2043 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70596
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Provided is an anti-CLL1 antibody and an application thereof. The variable region of the anti-CLL1 antibody includes the CDRs of SEQ ID NO: 1 to 6, SEQ ID NO: 5, and SEQ ID NO: 7 to 11 or SEQ ID NO: 12 to 17. The anti-CLL1 antibody of the present application has significant binding ability to both free and cell surface CLL1. After humanization, the affinity of the antibody to CLL1 is further improved, and it has important application prospect in the clinical diagnosis and/or treatment of tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.